Insulet Corporation (PODD)
| Market Cap | 11.39B -48.5% |
| Revenue (ttm) | 2.90B +31.9% |
| Net Income | 302.80M -24.7% |
| EPS | 4.29 -22.7% |
| Shares Out | 69.26M |
| PE Ratio | 38.33 |
| Forward PE | 24.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,498,525 |
| Open | 161.14 |
| Previous Close | 159.28 |
| Day's Range | 161.14 - 169.85 |
| 52-Week Range | 138.79 - 354.88 |
| Beta | 1.11 |
| Analysts | Strong Buy |
| Price Target | 237.21 (+44.26%) |
| Earnings Date | Aug 5, 2026 |
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controll... [Read more]
Financial Performance
In 2025, Insulet's revenue was $2.71 billion, an increase of 30.73% compared to the previous year's $2.07 billion. Earnings were $247.10 million, a decrease of -40.93%.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for PODD stock is "Strong Buy." The 12-month stock price target is $237.21, which is an increase of 44.26% from the latest price.
News
Insulet partners with Calm to provide resources for people living with diabetes
Insulet (PODD) announced a global partnership with Calm, a consumer mental health company, to provide emotional well-being resources for people living with diabetes, their caregivers, and healthcare p...
Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced a...
PODD Investors Have Rights - If You Lost Money Investing in Insulet Corporation Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, July 13, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Insulet Corporation (NASDAQ: PODD...
Insulet price target lowered to $210 from $219 at Truist
Truist lowered the firm’s price target on Insulet (PODD) to $210 from $219 and keeps a Buy rating on the shares as part of a broader research note on Diabetes…
Insulet price target lowered to $245 from $280 at RBC Capital
RBC Capital lowered the firm’s price target on Insulet (PODD) to $245 from $280 and keeps an Outperform rating on the shares as part of a broader research note previewing…
Insulet price target lowered to $225 from $250 at Stifel
Stifel analyst Jonathan Block lowered the firm’s price target on Insulet (PODD) to $225 from $250 and keeps a Buy rating on the shares. Survey results suggest modest growth in…
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 31, 2026 in Insulet Corporation Lawsuit - PODD
Notice to Pension Funds, Asset Managers, and Fiduciaries Holding PODD: Institutional Portfolios Face Significant Exposure Following Two Omnipod Medical Device Corrections and Over $90 Per Share Declin...
Insulet price target raised to $172 from $165 at Citi
Citi raised the firm’s price target on Insulet (PODD) to $172 from $165 and keeps a Neutral rating on the shares. For Q2 earnings season, given “the skittish trading environment,”…
INSULET CORPORATION (PODD) INVESTOR ALERT Investors With Large Losses in Insulet Corporation Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
Insulet price target lowered to $180 from $200 at Evercore ISI
Evercore ISI lowered the firm’s price target on Insulet (PODD) to $180 from $200 and keeps an Outperform rating on the shares. The firm’s Q2 preview for MedTech, Life Sciences…
Insulet announces launch of Omipod 5, Omnipod Discover in Spain
Insulet (PODD) Corporation announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System and its proprietary data management system Omnipod Discover in Spain, the Company’s newest...
Insulet Slides: Investor presentation
Insulet has posted slides in relation to its latest quarterly earnings report, which was published on July 6, 2026.
Grabar Law Office Investigates Claims on Behalf of Shareholders of Insulet Corporation (PODD)
Philadelphia, Pennsylvania--(Newsfile Corp. - July 3, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Insulet Corporation (NASDAQ: PODD). WHAT IS THIS INVESTIGATION ABOU...
FDA says Insulet recalled certain Omnipod Pods
The FDA said it is aware that Insulet (PODD) issued a letter to affected customers recommending certain Omnipod Pods be removed from where they are used or sold. The affected…
Insulet to Announce Second Quarter 2026 Financial Results on August 5, 2026
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Insulet appoints Mazelsky to its Board of Directors
Insulet (PODD) Corporation announced the appointment of Jonathan Mazelsky to the Company’s Board of Directors, effective July 1, 2026. Mazelsky joins the Board as an independent director. Published fi...
Insulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...
Insulet initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Kieran Ryan initiated coverage of Insulet (PODD) with a Buy rating and $190 price target The firm acknowledges potential headwinds over time from competition in tubeless and…
Insulet initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of Insulet (PODD) with a Buy rating and $190 price target
Insulet price target lowered to $219 from $250 at Truist
Truist lowered the firm’s price target on Insulet (PODD) to $219 from $250 and keeps a Buy rating on the shares after hosting an NDR meeting with Insulet’s management, including…
Insulet price target lowered to $216 from $263 at Raymond James
Raymond James lowered the firm’s price target on Insulet (PODD) to $216 from $263 and keeps an Outperform rating on the shares. The firm noted that there continues to be…
Insulet announces new results on tubeless AID systems
Insulet (PODD) announced new clinical results highlighting the “next breakthroughs” in tubeless Automated Insulin Delivery, AID, systems. The data and growing body of evidence not only confirm the imp...
CDRH issues Early Alert about pump issue from Insulet
The FDA is aware that Insulet (PODD) has issued a letter to affected customers recommending certain Omnipod Pods be removed from where they are used or sold, the agency noted.
Insulet announces planned activities during ADA Scientific Sessions
Insulet (PODD) announced its planned activities during the American Diabetes Association, ADA, 86th Scientific Sessions, taking place June 5 – 8, 2026 in New Orleans. Insulet’s presence at ADA highlig...